[Nintedanib in lung cancer]
González L, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A
Record ID 32017000303
Spanish
Authors' recommendations:
Moderate quality evidence showed that adding nintedanib to chemotherapy with docetaxel or pemetrexed as second-line regimens would not improve overall survival or quality of life of advanced lung cancer patients. Low quality evidence reports that the use with docetaxel in patients with adenocarcinoma, and mainly in those who progressed before nine months after initiating the first line of treatment, might increase overall survival in approximately three months.
In general, guidelines do not mention it as standard of care. Most health sponsors consulted do not cover it. In the United Kingdom, the use is covered by the public healthcare system as a treatment option only if there is an agreement on its price, which should be five times lower than the price stated in Argentina.
Details
Project Status:
Completed
Year Published:
2017
URL for published report:
www.iecs.org.ar/home-ets/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Protein Kinase Inhibitors
- Lung Neoplasms
- Antineoplastic Agents
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
<p>Institute for Clinical Effectiveness and Health Policy (IECS)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.